Colcrys gains indication for gout flare prevention

Colcrys (colchicine tablets, from AR Scientific) has been approved by the FDA for the prophylaxis of gout flares. This approval was based on data from two randomized clinical trials that assessed the efficacy of colchicine for the prophylaxis of gout flares in patients initiating treatment with uric-acid lowering therapy. Treatment with colchicine decreased the frequency of gout flares in both trials.

Colcrys is available as a 0.6mg dosage strength tablet. It is already indicated for the treatment of acute gout flares when taken at the first sign of a flare and for the treatment of familial Mediterranean fever (FMF) in adults and children ≥4 years of age.

For more information call (800) 523-3684 or visit www.colcrys.com.